CN110386922A - 治疗活性化合物及其使用方法 - Google Patents

治疗活性化合物及其使用方法 Download PDF

Info

Publication number
CN110386922A
CN110386922A CN201910708167.6A CN201910708167A CN110386922A CN 110386922 A CN110386922 A CN 110386922A CN 201910708167 A CN201910708167 A CN 201910708167A CN 110386922 A CN110386922 A CN 110386922A
Authority
CN
China
Prior art keywords
compound
crystalline form
dose
trifluoromethyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910708167.6A
Other languages
English (en)
Chinese (zh)
Inventor
塞缪尔·V·阿格雷斯塔
顾重晖
戴维·辛凯因
杨桦
郭丽婷
汤臻
汪建明
张炎锋
周燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2013/081170 external-priority patent/WO2015018060A1/en
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CN110386922A publication Critical patent/CN110386922A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CN201910708167.6A 2013-08-02 2014-08-01 治疗活性化合物及其使用方法 Pending CN110386922A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201361861884P 2013-08-02 2013-08-02
US61/861,884 2013-08-02
PCT/CN2013/081170 WO2015018060A1 (en) 2013-08-09 2013-08-09 Crystalline forms of therapeutically active compounds and use thereof
CNPCT/CN2013/081170 2013-08-09
US201461939098P 2014-02-12 2014-02-12
US61/939,098 2014-02-12
US201461975448P 2014-04-04 2014-04-04
US61/975,448 2014-04-04
US201462011948P 2014-06-13 2014-06-13
US62/011,948 2014-06-13
CN201480053796.5A CN105916507A (zh) 2013-08-02 2014-08-01 治疗活性化合物及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480053796.5A Division CN105916507A (zh) 2013-08-02 2014-08-01 治疗活性化合物及其使用方法

Publications (1)

Publication Number Publication Date
CN110386922A true CN110386922A (zh) 2019-10-29

Family

ID=52432592

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201910708167.6A Pending CN110386922A (zh) 2013-08-02 2014-08-01 治疗活性化合物及其使用方法
CN201480053796.5A Pending CN105916507A (zh) 2013-08-02 2014-08-01 治疗活性化合物及其使用方法
CN201910707312.9A Active CN110372670B (zh) 2013-08-02 2014-08-01 治疗活性化合物及其使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201480053796.5A Pending CN105916507A (zh) 2013-08-02 2014-08-01 治疗活性化合物及其使用方法
CN201910707312.9A Active CN110372670B (zh) 2013-08-02 2014-08-01 治疗活性化合物及其使用方法

Country Status (21)

Country Link
US (6) US9738625B2 (https=)
EP (3) EP3027193A4 (https=)
JP (3) JP6742905B2 (https=)
CN (3) CN110386922A (https=)
AU (2) AU2014295938B2 (https=)
BR (1) BR112016002287A2 (https=)
CA (1) CA2919382A1 (https=)
CL (2) CL2016000263A1 (https=)
EA (1) EA030428B1 (https=)
ES (1) ES2886211T3 (https=)
IL (2) IL243833A0 (https=)
MX (2) MX389250B (https=)
MY (1) MY177994A (https=)
NI (1) NI201600022A (https=)
PE (1) PE20160840A1 (https=)
PH (1) PH12016500164B1 (https=)
SA (1) SA516370523B1 (https=)
SG (2) SG10201709187TA (https=)
TW (2) TWI666208B (https=)
UA (1) UA121021C2 (https=)
WO (1) WO2015017821A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
TWI666208B (zh) * 2013-08-02 2019-07-21 美商阿吉斯藥品有限公司 治療活性化合物及其使用方法（三）
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN107531675A (zh) 2015-02-04 2018-01-02 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
WO2016177347A1 (en) * 2015-05-07 2016-11-10 Teligene Ltd Heterocyclic compounds as idh2 inhibitors
TWI722004B (zh) 2015-07-30 2021-03-21 大陸商正大天晴藥業集團股份有限公司 1,3,5-三嗪衍生物及其使用方法
CA2993615A1 (en) 2015-08-05 2017-02-09 Agios Pharmaceuticals, Inc. Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines
CN108366980A (zh) 2015-10-15 2018-08-03 安吉奥斯医药品有限公司 用于治疗恶性肿瘤的组合疗法
US10695352B2 (en) * 2015-10-15 2020-06-30 Celgene Corporation Combination therapy for treating malignancies
US9688659B2 (en) * 2015-10-21 2017-06-27 NeuForm Pharmaceuticals, Inc. Deuterated compounds for treating hematologic malignancies, and compositions and methods thereof
IL298663A (en) * 2015-12-04 2023-01-01 Agios Pharmaceuticals Inc Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras
WO2017140758A1 (en) 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
ES2912909T3 (es) 2016-02-26 2022-05-30 Celgene Corp Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria
EP3493809B1 (en) 2016-08-03 2023-08-23 Celgene Corporation Enasidenib for treatment of myelodysplastic syndrome
JP7093764B2 (ja) * 2016-08-03 2022-06-30 セルジーン コーポレイション 骨髄異形成症候群の治療方法
MX392941B (es) 2016-09-07 2025-03-24 Celgene Corp Composiciones para comprimidos.
WO2018133856A1 (zh) * 2017-01-22 2018-07-26 正大天晴药业集团股份有限公司 1，3，5-三嗪衍生物的盐及其晶体、它们的制备方法、药物组合物和用途
WO2018204787A1 (en) 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
EP4201399A3 (en) 2017-06-30 2023-08-09 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2021097160A1 (en) 2019-11-14 2021-05-20 Celgene Corporation Pediatric formulations for treatment of cancer
CN114773320A (zh) * 2022-05-29 2022-07-22 重庆医科大学 1,3,5-三嗪化合物及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679321A (zh) * 2007-04-30 2010-03-24 普罗米蒂克生物科学公司 三嗪衍生物、含所述衍生物的组合物以及使用所述衍生物治疗癌症和自身免疫性疾病的方法
CN102573485A (zh) * 2009-06-08 2012-07-11 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
US20130190287A1 (en) * 2012-01-06 2013-07-25 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
EP0466647B1 (de) 1990-07-12 1995-11-29 Ciba-Geigy Ag Verfahren zur photochemischen und thermischen Stabilisierung von Polyamid-Fasermaterialien
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
WO2000075129A1 (en) 1999-06-07 2000-12-14 Shire Biochem Inc. Thiophene integrin inhibitors
US7291616B2 (en) * 2001-10-31 2007-11-06 Cell Therapeutics, Inc. Aryl triazines as LPAAT-β inhibitors and uses thereof
EP1546121B1 (en) 2002-07-18 2012-08-29 Janssen Pharmaceutica NV Substituted triazine kinase inhibitors
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US8486939B2 (en) * 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2013133367A1 (ja) 2012-03-09 2013-09-12 カルナバイオサイエンス株式会社 新規トリアジン誘導体
MY185687A (en) 2013-07-11 2021-05-30 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
TWI666208B (zh) 2013-08-02 2019-07-21 美商阿吉斯藥品有限公司 治療活性化合物及其使用方法（三）
AU2015324158A1 (en) * 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN107531675A (zh) 2015-02-04 2018-01-02 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679321A (zh) * 2007-04-30 2010-03-24 普罗米蒂克生物科学公司 三嗪衍生物、含所述衍生物的组合物以及使用所述衍生物治疗癌症和自身免疫性疾病的方法
CN102573485A (zh) * 2009-06-08 2012-07-11 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
US20130190287A1 (en) * 2012-01-06 2013-07-25 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李全林: "《新医药开发与研究（下册）》", 31 December 2008 *

Also Published As

Publication number Publication date
IL243833A0 (en) 2016-04-21
EP3027193A4 (en) 2017-04-26
CN110372670B (zh) 2023-04-07
CN110372670A (zh) 2019-10-25
CN105916507A (zh) 2016-08-31
JP2021176893A (ja) 2021-11-11
MX2016001361A (es) 2016-06-14
US9738625B2 (en) 2017-08-22
MX2020011397A (es) 2022-08-05
SG11201600479WA (en) 2016-02-26
EA030428B1 (ru) 2018-08-31
MX389250B (es) 2025-03-20
TWI666208B (zh) 2019-07-21
NZ716226A (en) 2021-08-27
EP3027193A2 (en) 2016-06-08
PE20160840A1 (es) 2016-09-22
NI201600022A (es) 2016-03-16
US20240132474A1 (en) 2024-04-25
US20210155603A1 (en) 2021-05-27
WO2015017821A3 (en) 2015-04-09
AU2018247242A1 (en) 2018-11-01
EP3932408A1 (en) 2022-01-05
TW201932455A (zh) 2019-08-16
PH12016500164B1 (en) 2023-11-08
AU2014295938B2 (en) 2018-07-19
AU2014295938A1 (en) 2016-02-18
SG10201709187TA (en) 2017-12-28
US20260085059A1 (en) 2026-03-26
CL2017002240A1 (es) 2018-04-20
AU2018247242B2 (en) 2020-03-12
US10093654B2 (en) 2018-10-09
SA516370523B1 (ar) 2019-01-10
US10730854B2 (en) 2020-08-04
EP3566706A1 (en) 2019-11-13
IL270347B (en) 2021-08-31
UA121021C2 (uk) 2020-03-25
MY177994A (en) 2020-09-28
WO2015017821A2 (en) 2015-02-05
CA2919382A1 (en) 2015-02-05
CL2016000263A1 (es) 2016-08-19
JP2019142930A (ja) 2019-08-29
MX394658B (es) 2025-03-24
EA201690322A1 (ru) 2016-07-29
US20160194305A1 (en) 2016-07-07
EP3566706B1 (en) 2021-07-14
JP6742905B2 (ja) 2020-08-19
TW201524971A (zh) 2015-07-01
US20170305885A1 (en) 2017-10-26
PH12016500164A1 (en) 2016-04-25
US20180370951A1 (en) 2018-12-27
ES2886211T3 (es) 2021-12-16
TWI701242B (zh) 2020-08-11
BR112016002287A2 (pt) 2017-08-01
JP2016527279A (ja) 2016-09-08

Similar Documents

Publication Publication Date Title
US20260085059A1 (en) Therapeutically active compounds and their methods of use
US10434105B2 (en) Therapeutically active compounds and their methods of use
KR102316886B1 (ko) 치료학적 활성 화합물 및 이의 사용방법
HK40016190A (en) Therapeutically active compounds and their methods of use
HK40016189A (en) Therapeutically active compounds and their methods of use
HK40016189B (en) Therapeutically active compounds and their methods of use
HK40016900B (en) Therapeutically active compounds and their methods of use
HK40016900A (en) Therapeutically active compounds and their methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40016190

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20221209

Address after: France

Applicant after: LES LABORATOIRES SERVIER

Address before: Massachusetts

Applicant before: AGIOS PHARMACEUTICALS, Inc.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20191029